Stock Market

BTIG Lowers Humacyte Target, Still Sees Bigger Opportunity Ahead

By Bullbit Editorial · March 29, 2026

• WhatBTIG cut its target on Humacyte (HUMA) shares.
• WhyThe firm cited valuation concerns.
• SignalThis move suggests a cautious approach to the stock.
• TargetHumacyte's long-term potential remains intact.
• RiskInvestors should weigh the risks against the potential reward.

More breaking news →